MedTrace Logo

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-07-29

No results posted yet for this study

Summary

The purpose of this research study is to identify a way to improve the feeling of exhaustion that patients might experience because of Multiple Sclerosis (MS).

Conditions

Interventions

DRUG

L-Histidine

1000 mg capsules taken by mouth (PO) twice daily (BID).

DRUG

Placebo

Microcrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).

DRUG

Lodosyn

50 mg capsules taken PO BID.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Kottil Rammohan, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-10-30
Completion
2022-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04764383 on ClinicalTrials.gov